[{"orgOrder":0,"company":"SYMATESE FR 69630 Chaponost","sponsor":"Evolus","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Protein","year":"2025","type":"Collaboration","leadProduct":"Botulinum toxin type A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"SYMATESE FR 69630 Chaponost","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SYMATESE FR 69630 Chaponost \/ Evolus","highestDevelopmentStatusID":"15","companyTruncated":"SYMATESE FR 69630 Chaponost \/ Evolus"}]

Find Clinical Drug Pipeline Developments & Deals by SYMATESE FR 69630 Chaponost

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : The collaboration with Evolus aims to expand Nuceiva (Botulinum Toxin Type A) in France. It is being indicated for the treatment of glabellar lines.

                          Product Name : Nuceiva

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          July 09, 2025

                          Lead Product(s) : Botulinum toxin type A

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Evolus

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank